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Long non-coding RNA HOTAIR 
promotes cell migration by 
upregulating insulin growth  
factor–binding protein 2 in renal cell 
carcinoma
Hiromichi Katayama1,6, Keiichi Tamai1, Rie Shibuya1, Mao Nakamura2, Mai Mochizuki1, 
Kazunori Yamaguchi2, Sadafumi Kawamura  3, Tatsuo Tochigi3, Ikuro Sato4, Takamasa 
Okanishi5, Kunie Sakurai5, Wataru Fujibuchi5, Yoichi Arai6 & Kennichi Satoh1
Renal cell carcinoma (RCC) is one of the most lethal urologic cancers. About one-third of RCC patients 
already have distal metastasis at the time of diagnosis. There is growing evidence that Hox antisense 
intergenic RNA (HOTAIR) plays essential roles in metastasis in several types of cancers. However, the 
precise mechanism by which HOTAIR enhances malignancy remains unclear, especially in RCC. Here, 
we demonstrated that HOTAIR enhances RCC-cell migration by regulating the insulin growth factor-
binding protein 2 (IGFBP2) expression. HOTAIR expression in tumors was significantly correlated with 
nuclear grade, lymph-node metastasis, and lung metastasis. High HOTAIR expression was associated 
with a poor prognosis in both our dataset and The Cancer Genome Atlas dataset. Migratory capacity 
was enhanced in RCC cell lines in a HOTAIR-dependent manner. HOTAIR overexpression accelerated 
tumorigenicity and lung metastasis in immunodeficient mice. Microarray analysis revealed that IGFBP2 
expression was upregulated in HOTAIR-overexpressing cells compared with control cells. The enhanced 
migration activity of HOTAIR-overexpressing cells was attenuated by IGFBP2 knockdown. IGFBP2 and 
HOTAIR were co-expressed in clinical RCC samples. Our findings suggest that the HOTAIR-IGFBP2 axis 
plays critical roles in RCC metastasis and may serve as a novel therapeutic target for advanced RCC.
Renal cell carcinoma (RCC), which accounts for about 3% of all cancers in adults, is the most lethal of all uro-
logical malignancies1. One-third of RCC patients already have metastases at the time of diagnosis, and 20–30% 
of patients treated by radical nephrectomy will suffer metastasis or recurrence2. The prognosis of metastatic 
RCC is poor: the median survival is about 13 months3. Although recent developments in targeted therapy have 
improved survival rates for metastatic RCC, most patients still succumb to the disease. Therefore, new therapeutic 
approaches and prognostic factors are needed to treat advanced RCC.
Although numerous lncRNAs (non-coding RNAs longer than 200 nucleotides)4 have been identified as factors 
in cancer progression and the development and spread of metastases5, lncRNAs also regulate a wide variety of cell 
functions in normal tissue. Since many lncRNAs are differentially expressed in specific organs, tissues, or cancer 
types, lncRNAs are potential prognostic markers4.
Hox antisense intergenic RNA (HOTAIR), a lncRNA that acts as an oncogenic molecule in various types of 
cancer, is localized to the HOXC gene cluster. HOTAIR interacts with PRC2 (polycomb repressive complex 2) 
to enhance H3K27 trimethylation, and thereby decreases the expression of a large number of genes6. Several 
groups, including our laboratory, have reported that high HOTAIR expression is correlated with a poor prognosis 
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in several types of cancer, including breast7, colorectal8, cervical9, non-small lung cell10, and gastric cancer11. 
However, the underlying mechanism by which HOTAIR is involved in malignancy remains uncertain. Many 
downstream molecules of HOTAIR have been identified: in breast cancer, HOTAIR increases cancer invasiveness 
and metastasis in a manner dependent on PRC27. In esophageal squamous cell carcinoma, HOTAIR decreases 
WIF-1 expression and activates the Wnt/β-catenin signaling pathway, thus promoting cell migration12. In cervical 
cancer, HOTAIR promotes tumor growth and invasion by targeting the Notch pathway13. However, there are few 
reports addressing HOTAIR’s molecular mechanism in RCC.
Insulin growth factor-binding protein 2 (IGFBP2) belongs to a family of six IGF-binding proteins, IGFBP1–6. 
These proteins bind to IGF1 and IGF2. The IGFBP2 expression is elevated in many cancer types, in both tumor 
cells and plasma14–16. Although conventionally known as the IGF regulatory protein, IGFBP was recently demon-
strated to have pro-tumorigenic activity that is independent of IGF signaling in glioma cells: IGFBP2 contributes 
to cancer progression by enhancing MMP2 (matrix metalloprotease 2) gene transcription and, in turn, tumor-cell 
invasion17. IGFBP2 also binds integrin alpha 5 and activates pathways downstream of integrin, increasing cell 
motility18. Exogenous IGFBP2 promotes glioma-cell proliferation and invasion capability via the ERK pathway, 
which is activated by integrin β1 signaling19. However, it is not known how IGFBP2 is regulated in cancer cells, or 
whether IGFBP2 has oncogenic activity in RCC.
In this study, we analyzed correlations between HOTAIR expression and clinical characteristics in 64 RCCs. 
We clarified HOTAIR’s role in RCC and identified IGFBP2 as a molecule downstream of HOTAIR that is involved 
in RCC migratory capacity and prognosis.
Results
HOTAIR expression and clinicopathological characteristics in RCC. To evaluate correlations 
between HOTAIR expression and clinical characteristics, we examined the HOTAIR expression in 64 RCCs and 
their corresponding normal renal tissues using quantitative real-time PCR. We analyzed clinicopathological fea-
tures such as age, gender, stage, T stage, N stage, M stage, nuclear grade, and vascular invasion, and measured 
the tumor HOTAIR expression relative to that in corresponding normal tissues. The cut-off point was deter-
mined according to the survival receiver operating characteristic (ROC) curve; tumors with HOTAIR levels at 
least 1.2-fold higher than that in the corresponding normal tissue were defined as high-expression, and those 
with HOTAIR levels below this threshold were defined as low-expression (Fig. 1A). We found that HOTAIR 
expression was associated with vascular invasion, nuclear grade, lymph-node metastasis, and distant metasta-
sis (Table 1). Next, we analyzed the relationship between HOTAIR expression and patient prognosis using the 
Kaplan-Meier method. HOTAIR expression was significantly associated with a shorter survival in RCC patients 
(Fig. 1B). These results suggested that high HOTAIR expression indicates a poorer prognosis in RCC. To confirm 
this correlation, we searched TCGA and obtained the gene expression data and patient prognosis for 521 samples. 
Again, we found that high HOTAIR expression was significantly correlated with a poor prognosis (Fig. 1C). These 
data indicated that HOTAIR plays a critical role in RCC.
Enhanced RCC-cell migration by HOTAIR in vitro. Since high HOTAIR expression was significantly 
associated with metastasis and prognosis in patients with RCC, we used two human RCC cell lines to generate 
cells that stably overexpressed HOTAIR (Fig. 2A,B). These HOTAIR-transduced cells overexpressed HOTAIR at 
levels 6-fold higher (ACHN-HOTAIR) and 30-fold higher (A498-HOTAIR) than did empty vector (EV)–trans-
duced cells. In Caki-1 cells, which had higher endogenous HOTAIR expression than the ACHN or A498 RCC 
cell lines (Supplementary Fig. S1), knocking down HOTAIR by transfection with small interfering RNA (siRNA) 
decreased the HOTAIR expression by 55–66% (Fig. 2C).
We assayed the effect of HOTAIR on cell proliferation using a cell-counting kit and found that the HOTAIR 
overexpression in ACHN and A498 cells did not alter their proliferation compared to control cells (Fig. 2D,E). 
HOTAIR siRNA knockdown did not affect cell proliferation in Caki-1 cells (Fig. 2F).
We evaluated HOTAIR’s role in migratory capability with a two-chamber assay and found that the migrated 
cells included significantly more HOTAIR-transduced than EV-transduced ACHN and A498 cells (Fig. 2G,H, 
and Supplementary Figure S2), and significantly fewer HOTAIR-knockdown than control Caki-1 cells (Fig. 2I). 
Similarly, a wound-healing assay showed that migration capacity was significantly enhanced by HOTAIR overex-
pression, but diminished by its knockdown (Fig. 2J–L). These data indicated that HOTAIR plays a critical role in 
the RCC cells’ migratory capacity.
Effect of HOTAIR overexpression on ACHN cells in vivo. To evaluate the malignant characteristics of 
HOTAIR-expressing cancer cells in vivo, we assayed their tumorigenicity using NOD/Shi-scid-IL2Rγnull (NOG) 
mice. When injected subcutaneously, HOTAIR-overexpressing cells grew faster than control cells (Fig. 3A). 
HOTAIR overexpression in cells introduced by tail-vein injection (Fig. 3B,C) or orthotopic xenograft (Fig. 3D,E) 
significantly increased the number of lung metastases. These data suggested that HOTAIR overexpression 
enhanced the colonization and metastasis of RCC cells in vivo.
Induction of IGFBP2 expression by HOTAIR. Since our results showed that HOTAIR regulates can-
cer invasiveness and metastasis both in vitro and in vivo, we identified invasiveness-related genes that were 
upregulated in our microarray data for HOTAIR-overexpressing cells and were reported to be potentially 
oncogenic. After a search of the literature for each of the 11 genes that were upregulated most strongly in 
HOTAIR-overexpressing cells, as identified by the rank product algorithm, we chose IGFBP2 for further anal-
ysis because it has been identified as a key factor in malignancy, especially in cancer invasiveness (Fig. 4A)17–19. 
Western blots and real-time PCR results confirmed that IGFBP2 was upregulated in the ACHN-HOTAIR cells 
(Fig. 4B,C). Together, these results suggested that IGFBP2 acts downstream of HOTAIR in RCC.
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Attenuation of the enhanced migration of HOTAIR-overexpressing cells by IGFBP2 knock-
down. To test whether IGFBP2 regulates the migratory ability downstream of HOTAIR, we transfected 
ACHN-HOTAIR cells with siRNAs to knockdown the IGFBP2 gene, and confirmed that the IGFBP2 expression 
was significantly reduced in the transfected cells compared to control cells (Fig. 4D,E). Cell-proliferation assays 
revealed that 72 h after transfection, the proliferation was slightly reduced in the IGFBP2-knockdown cells com-
pared to cells transfected with control siRNA (Fig. 4F). Cell migration was clearly reduced in IGFBP2-knockdown 
cells compared to cells transfected with control siRNA, in both the two-chamber (Fig. 4G) and scratch assay 
(Fig. 4H). We also tested HOTAIR-overexpressing A498 cells. As with ACHN cells, IGFBP2 was upregulated 
by HOTAIR overexpression in A498 cells, and the ability of these cells to migrate was dependent on IGFBP2 
(Supplementary Figure S3, A to C). These results suggested that the migration of HOTAIR-overexpressing cells 
was mainly dependent on IGFBP2.
Correlation of HOTAIR expression with IGFBP2 in RCC tissues. To determine whether HOTAIR 
expression was correlated with IGFBP2 expression in human RCC tissues, we extracted the total RNA from 
resected RCC tissues and measured the IGFBP2 and HOTAIR expression by real-time PCR. We found that the 
IGFBP2 expression was positively correlated with the HOTAIR expression in RCC tissues (Table 2, Fisher’s exact 
test).
We used in situ hybridization (ISH) and immunohistochemistry (IHC) to confirm the HOTAIR and IGFBP2 
co-expression in RCC tissues. Figure 5 shows representative serial sections that underwent hematoxylin and eosin 
(HE) staining, ISH for HOTAIR, and IHC for IGFBP2. The section contained a typical clear-cell RCC with a low 
nuclear grade, and another with sarcomatoid differentiation and a high nuclear grade (Fig. 5A). In the low-grade 
tumor area, ISH and IHC detected only slight levels of HOTAIR and IGFBP2 (Fig. 5D,E,I,J). Higher levels of 
HOTAIR and IGFBP2 were detected in the high-grade tumor area (Fig. 5G–J).
Figure 1. HOTAIR expression in RCCs (A) HOTAIR expression in 64 RCCs and their corresponding normal 
renal tissues was measured by quantitative real-time PCR. (B) Kaplan-Meier curves for cancer-specific survival 
according to HOTAIR expression in 64 RCC patients. (C) Kaplan-Meier curves for overall survival ratio 
according to HOTAIR expression in the RCC patient dataset obtained from TCGA (n = 521). Differences 
between groups were compared by log-rank test.
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IGFBP2 is a prognostic factor in RCC. Finally, we investigated whether IGFBP2 was correlated with RCC 
prognosis. In our dataset, high IGFBP2 expression determined by real-time PCR was significantly associated with 
a poor prognosis (Fig. 6A). To confirm this correlation, we searched TCGA and obtained the gene expression data 
and patient prognosis for 521 samples. Again, we found that high IGFBP2 expression was significantly correlated 
with a poor prognosis (Fig. 6B). Interestingly, the group with high levels of both HOTAIR and IGFBP2 had the 
poorest prognosis (Supplementary Fig. S4). The prognosis for the HOTAIRlow-IGFBP2high group was almost the 
same as that for the HOTAIRlow-IGFBP2low group. (Fig. 6C). These data indicated that the regulation of IGFBP2 
by HOTAIR is critical in RCC development.
Discussion
In this study, we demonstrated that HOTAIR is involved in RCC. HOTAIR-overexpressing cells grew faster in an 
in vivo tumorigenicity assay but grew at a similar rate to control cells in vitro, suggesting that HOTAIR is involved 
in colonization capacity. Tail-vein injection and orthotopic xenograft assays indicated that HOTAIR induced col-
onization capacity in the lung. HOTAIR was associated with distant and lymph-node metastases in RCC patients. 
Collectively, these data suggested that HOTAIR plays critical roles in RCC’s ability to invade and colonize. A 
previous study showed that HOTAIR knockdown in RCC cell lines decreased their migration in vitro20, which is 
compatible with our present study.
We also demonstrated that the presence of both HOTAIR and IGFBP2 in RCC is a prognostic marker in 
RCC, suggesting that the HOTAIR-IGFBP2 axis may represent a specific therapeutic target for RCC. Because the 
HOTAIRlow-IGFBP2high group had a better prognosis than the HOTAIRhigh-IGFBP2high group, we speculate that 
HOTAIR-dependent IGFBP2 expression is important for the progression of RCC. IGFBP2 overexpression is well 
documented in tumors, including glioma21, breast cancer22,23, ovarian cancer24, prostate cancer25, colorectal cancer26, 
gastric cancer27, lung cancer28, leukemia29, and astrocytoma30. Recent studies implicate elevated IGFBP2 in a shorter 
overall survival time31–33. In glioma cells, IGFBP2’s interaction with integrin alpha 5 is essential for cell mobility18, 
and the IGFBP2/integrin/ILK/NF-κB signaling pathway drives cancer progression in vivo34. Although the precise 
molecular mechanisms of cell invasion in RCC are unknown, IGFBP2 may be critical for this progression.
Group
HOTAIR-Low 
N = 43 (%)
HOTAIR-High 
N = 21(%) P-valuea
Age 0.787
 ≥60 years 29 (67) 13 (61)
 <60 years 14 (33) 8 (39)
Sex 0.16
 Male 27 (63) 17 (81)
 Female 16 (37) 4 (19)
Types of nephrectomy 0.153
 Radical 26 (60) 17 (81)
 Partial 17 (40) 4 (19)
Fuhrman’s nuclear grade 0.0038
 Grades 1–2 40 (93) 13 (61)
 Grades 3–4 3 (7) 8 (39)
Vascular invasion 0.0138
 No 31 (72) 8 (39)
 Yes 12 (28) 13 (61)
Tumor diameter 0.057
 <4 cm 19 (44) 4 (19)
 ≥4 cm 24 (56) 17 (81)
T stage 0.068
 T1 + T2 35 (81) 12 (57)
 T3 + T4 8 (19) 9 (43)
N stage 0.0027
 N0 43 (100) 16 (76)
 N1–2 0 (0) 5 (24)
M stage 0.0135
 M0 39 (91) 13 (61)
 M1 4 (9) 8 (39)
TNM stage 0.0025
 Stage I-II 32 (74) 7 (33)
 Stage III-IV 11 (26) 14 (67)
Table 1. HOTAIR expression and clinicopathological characteristics in RCC. aThe statistical significance of 
differences between two groups was estimated by Fisher’s exact test.
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Several reports suggest that HOTAIR affects the expression of numerous genes involved in various cellular 
functions, especially those related to epithelial-mesenchymal transition (EMT)7. HOTAIR acts in esophageal 
squamous cell carcinoma by activating the Wnt/β-catenin signaling pathway12. In gastric cancer, inhibiting 
Figure 2. HOTAIR enhanced the migration of RCC cells in vitro (A,B) HOTAIR expression in ACHN and 
A498 cells transduced with a HOTAIR-overexpressing (HOTAIR) or empty vector (EV), determined by real-
time PCR. (C) HOTAIR expression levels in HOTAIR-targeted siRNA-transfected Caki-1 cells, determined 
by real-time PCR. (D,E, and F) Cell-proliferation CCK-8 assays in the indicated cell lines. (G,H, and I) Two-
chamber assays using HOTAIR-overexpressing (G,H) or knockdown cells (I) in arbitrary units (a.u.). (J to L) 
Wound-healing assays. *P < 0.05, Mann-Whitney U test.
www.nature.com/scientificreports/
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HOTAIR reverses the EMT process and reduces invasiveness mediated by MMP1 and MMP335. In breast can-
cer, TGFβ1 treatment induces EMT via HOTAIR expression36. In the present study, we found that HOTAIR 
expression did not affect EMT-related genes (Supplementary Fig. S5). On the other hand, several reports indi-
cate HOTAIR’s involvement in pathways unrelated to EMT. Suppressing HOTAIR upregulates the HOXA5 
level and downregulates MMP2 and MMP9, which are critical players in tumor invasion and metastasis37. 
A recent report demonstrated that HOTAIR’s targets, including EMT-related genes, strongly depend on the 
type of cancer cell in urothelial cancer38. Collectively, HOTAIR primarily affects cell migration in RCC not via 
EMT signaling, but rather through an IGFBP2-related pathway, although it is not clear how HOTAIR regulates 
IGFBP2 expression.
Here, we newly identified IGFBP2 as a downstream molecule of HOTAIR, which is involved in the migratory 
capability of RCC cells. Our findings suggest that the HOTAIR-IGFBP2 axis plays critical roles in the progression 
of RCC, and presents a novel therapeutic target for advanced RCC treatment.
Materials and Methods
Ethics statement. This study was conducted according to the principles expressed in the Declaration of 
Helsinki and was approved by the Ethics Committees at the Miyagi Cancer Center Research Institute (Natori, 
Japan). Experimental protocols involving animals were approved by the Miyagi Cancer Center Animal Care and 
Use Committee.
Clinical samples. Sixty-four RCC samples and their corresponding normal renal tissues were obtained 
from patients who underwent nephrectomy or partial nephrectomy at the Miyagi Cancer Center between 2007 
and 2015. All specimens ware immediately frozen and stored at −80 °C until RNA extraction. The Institutional 
Review Board of the Miyagi Cancer Center approved this study protocol, and each patient provided informed, 
Figure 3. In vivo effects of HOTAIR overexpression in ACHN cells (A) Tumorigenicity was assayed by injecting 
HOTAIR-overexpressing or control cells subcutaneously into NOG mice; graph shows average tumor volume 
and standard error. (B) HOTAIR-overexpressing or control cells injected into the tail vein of NOG mice; 24 
weeks later, metastatic pulmonary nodules were counted microscopically. (C) Representative images of lung 
metastatic nodules resulting from tail-vein injections; the dotted circles indicate metastatic foci. (D) Mice 
received orthotopic xenografts of HOTAIR-overexpressing or control cells, and pulmonary nodules were 
counted microscopically 14 weeks later. (E) Representative images of lung metastatic nodules in the orthotopic 
xenograft assay; the dotted circles indicate metastatic foci*.P < 0.05, Mann–Whitney U test.
www.nature.com/scientificreports/
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written consent. No patient received any neoadjuvant therapy, such as molecularly targeted therapy, before sur-
gery. All tumor tissues were diagnosed pathologically as clear cell RCC. The significance of differences between 
two groups was estimated by Fisher’s exact test.
Figure 4. s migration in HOTAIR-expressing cells was attenuated by IGFBP2 knockdown (A) Heatmap 
showing the expression profiles of 11 genes in HOTAIR-overexpressing (HOTAIR1–3) and control (EV1–4) 
ACHN cells as determined by microarray analysis using the rank product algorithm. Red and green indicate 
higher and lower expression, respectively. (B, C) IGFBP2 expression was determined by real-time PCR (B) and 
western blotting (C) in HOTAIR-overexpressing ACHN cells (HOTAIR) and control cells (EV). (D) IGFBP2 
expression was determined by real-time PCR in ACHN-EV cells transfected with control siRNA, ACHN-
HOTAIR cells transfected with control siRNA, and ACHN-HOTAIR cells transfected with siRNA against 
HOTAIR. (E) IGFBP2 level in ACHN cells was measured by western blotting. (F) ACHN cells were transfected 
with the indicated siRNA, and cell proliferation was assayed 72 h later by CCK-8. (G, H) Migration measured by 
two-chamber assay (G) and wound-healing assay (H) in ACHN cells transfected with siRNA against IGFBP2 as 
indicated in (D); a. u., arbitrary units. *P < 0.05 by Mann-Whitney U test. Unprocessed original scans of blots 
are shown in Supplementary Figure S6.
www.nature.com/scientificreports/
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N = 64 HOTAIR-Low HOTAIR-High P-value*
IGFBP2-Low 20 (31%) 12 (19%)
0.04
IGFBP2-High 11 (17%) 21 (33%)
Table 2. Correlation of the HOTAIR and the IGFBP2 expression in RCC. *Fisher’s exact test.
Figure 5. HOTAIR and IGFBP2 colocalization in high-grade tumor areas (A) Whole-section, low-
magnification view of an HE-stained renal-cell carcinoma containing both low-grade and high-grade tumors. 
(B) Immunohistochemistry (IHC) for IGFBP2, at low magnification. (C to E) Serial sections of the low-grade 
tumor area at high magnification, showing HE staining (C), ISH for HOTAIR (D), and IHC for IGFBP2 (E). 
(F to H) Serial sections of the high-grade tumor area at high magnification, showing HE staining (F), ISH for 
HOTAIR (G), and IHC for IGFBP2 (H). The black arrowheads indicate dot-like positive staining of HOTAIR. 
(I and J) Quantification of areas positive for HOTAIR (ISH, red) and IGFBP2 (IHC, brown) using ImageJ 
software. Total eight areas were randomly selected from low- and high-grade tumor areas. *P < 0.001.
www.nature.com/scientificreports/
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Validation with TCGA data. Clinical and pathological data were manually extracted from reports down-
loaded from the TCGA Data Portal (https://gdc-portal.nci.nih.gov/); gene expression profiles and clinical data 
from 521 patients with clear cell renal carcinoma were available from the website. Tumors with HOTAIR expres-
sion of at least 0.3 FPKM (fragments per kilobase of exon per million fragments mapped) were classified as 
high HOTAIR, and those with less than 0.3 FPKM as low HOTAIR. Tumors with IGFBP2 expression of at least 
6 FPKM were classified as high IGFBP2, and those with less than 6 FPKM as low IGFBP2. The Kaplan-Meier 
method for gene expression-specific survival analysis was performed using package “survival” in statistical com-
puting language R, and the statistical significance of survival curves between different expression levels (high- and 
low-) was evaluated by log-rank test.
RNA preparation, cDNA synthesis, and quantitative real-time RT-PCR. Total RNA was extracted 
from frozen samples and RCC cell lines by ISOGENE (Nippon Gene, Tokyo, Japan) according to the manufactur-
er’s protocol. For all samples, cDNAs were synthesized from 1.0 μg of total RNA with the PrimeScript 1st Strand 
cDNA Synthesis Kit (TaKaRa Bio, Shiga, Japan) following the manufacturer’s protocol.
HOTAIR expression was quantified as previously described39. The primer sequences used: for GAPDH, 
F 5′-TGAAGGTCGGAGTCAACGG-3′ and R 5′-AGAGTTAAAAGCAGCCCTGGTG-3′; for HOTAIR, 
F 5′-GGTAGAAAAAGCAACCACGAAGC-3′ and R 5′-ACATAAACCTCTGTCTGTGAGTGCC-3′; and 
for IGFBP2, F 5′-AGCCCAAGAAGCTGCGACCAC-3′ and R 5′-CTGCCCGTTCAGAGACATCTTGC-3′. 
HOTAIR expression was normalized to GAPDH expression in each sample. The HOTAIR expression in each 
RCC was determined relative to that in the corresponding normal renal tissue.
Cell lines and cell culture. Three clear-cell RCC cell lines (ACHN, A498, and Caki-1) were obtained 
from the Japanese Cancer Research Resources Bank, Tokyo, Japan (JCRB). The cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco/Life technologies, Carlsbad, USA) with 10% FBS and 1% 
penicillin-streptomycin. The cells were incubated in a humidified incubator at 37 °C and 5% CO2.
Figure 6. IGFBP2 is prognostic for RCC (A) Kaplan-Meier analysis for cancer-specific survival according to 
the IGFBP2 expression of in 64 RCC patients. The cut-off point was the median value in the current sample. 
(B) Kaplan-Meier curves for overall survival ratio according to IGFBP2 expression in the RCC patient dataset 
obtained from TCGA (n = 521). (C) Kaplan-Meier analysis for the cancer-specific survival rate of the four 
groups; differences between the groups were assessed by log-rank tests.
www.nature.com/scientificreports/
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Retroviral transfection. Human HOTAIR cDNA (obtained from Addgene, Cambridge, MA, USA) was 
amplified by PCR and inserted into the pBabe-hygro vector (pBabe-HOTAIR). The recombinant retrovirus was 
produced with the Platinum-A packaging-cell line (Plat-A, kindly provided by Prof. Kitamura, Tokyo University) 
as described previously40. Briefly, Plat-A cells were transfected with pBabe-HOTAIR or a pBabe-hygro empty 
vector (EV). Fugene 6 (Roche Applied Science) and Opti-MEM I (Gibco/Life Technologies Co.) were added 
following the manufacturer’s protocol. The retrovirus-containing supernatant was collected 48 h after transfec-
tion and passed through a 0.45-μm filter. ACHN cells were infected with the recombinant retroviruses and then 
selected with hygromycin.
siRNA transfection. The HOTAIR siRNAs #1 (FLJ41747HSSS160170), #2 (FLJ41747HSSS160171), the 
IGFBP2 siRNAs #1 (HSS142627) and #2 (HSS142629), and non-silencing control siRNA (12935–300) were pur-
chased from Invitrogen (Carlsbad, CA, USA). The siRNA transfections were performed using Lipofectamine 
RNAiMAX Reagent (Life Technologies, Carlsbad, CA, USA) in antibiotic-free medium for 48 h. The efficiency 
of siRNA knockdown was confirmed by real-time PCR (HOTAIR and IGFBP2) and western blotting (IGFBP2).
Cell-proliferation assay. Cell proliferation was detected with the Cell Counting Kit-8 (CCK-8) from 
Dojindo Laboratories (Kumamoato, Japan) according to the manufacturer’s protocol. Cells were seeded in 96-well 
plates (1 × 103 cells per well) in normal cell-growth medium. The relative numbers of viable cells at 0, 24, 48, 
72, and 96 h of incubation were assessed according to the absorbance of optical density at 450 nm detected by 
microplate reader (VersaMax, Molecular Devices, Sunnyvale, CA, USA).
Two-chamber assay. Cell migration was assessed using a two-chamber assay with a cell-culture insert 
(8-μm pore size, BD Biosciences, San Jose, CA, USA) in 24-well plates. Cells (5 × 104) were plated in each insert 
in serum-free medium. The bottom well contained medium with 10% FBS. After 48 h, the bottom of the insert 
was stained with Diff-Quick (Dade Behring Inc, Newark, DE, USA), and the cells that had invaded through the 
membrane to the lower surface were counted.
Wound-healing assay. Cells were seeded in 24-well plates in normal cell-growth medium, incubated until 
confluent, and treated with 5 μg/ml mitomycin C (Wako, Osaka, Japan) for 3 h. A yellow pipette tip was used to 
make a straight scratch, simulating a wound. The medium was changed to serum-free medium. After a 24 h incu-
bation, the area occupied by cells that had migrated into the scratch area was measured using ImageJ software.
Western blotting. Western blotting was performed as previously described with minor modifications39. 
In brief, whole-cell lysates were prepared in RIPA buffer supplemented with a proteinase-inhibitor cocktail. The 
lysates were clarified by centrifugation, the supernatant was boiled, and separated by SDS-PAGE. The following 
antibodies were used for western blots: anti-α-tubulin (Santa Cruz Biotechnology, Santa Cruz, CA, USA, B-5–1–
2) and anti-IGFBP2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA, C-18).
Animals. Six-week-old female NOG mice were purchased from the Central Institute for Experimental 
Animals (CIEA, Kawasaki, Japan). The mice were housed in a cleanroom at the animal care facility at Miyagi 
Cancer Research Center with standard temperature, humidity, and timed lighting, and given mouse chow/water 
ad libitum.
In vivo proliferation assay by subcutaneous injection. NOG mice were given subcutaneous injections 
of 1.0 × 104 ACHN cells transfected with a HOTAIR-overexpression (n = 8) or empty vector (n = 8) with 0.2 ml 
PBS. Tumors were measured weekly with a digital caliper, and tumor volume was calculated using the modified 
ellipsoid formula 1/2 (length × width2). The animals were sacrificed 8 weeks after the injection.
In vivo metastasis assays by orthotopic xenograft and tail-vein injection. For in vivo experimen-
tal metastasis assays, 1 × 104 ACHN-HOTAIR (n = 4) or ACHN-EV (n = 4) cells were injected into the tail vein 
of NOG mice. The mice were sacrificed 24 weeks later, and pulmonary nodules were assessed macroscopically 
and microscopically. The harvested organs were processed into paraffin-embedded sections, stained with HE, and 
examined pathologically to confirm the presence of metastatic lung tumors. In orthotopic xenograft implants, 
1 × 105 ACHN-HOTAIR (n = 4) or ACHN-EV (n = 3) cells in 20 μl matrigel were injected into the subcapsular 
area of the left kidney of the NOG mice. The mice were sacrificed 14 weeks later and the lungs were collected and 
analyzed. Pulmonary nodules were counted under a microscope.
Microarray analysis. A microarray analysis was performed to search for genes regulated by HOTAIR. We 
used the SurePrint G3 Human GE 8 × 60 K Microarray (Agilent Technologies, Santa Clara, CA, USA) to profile 
the gene expression in control and HOTAIR-overexpressing ACHN cells. The obtained gene expression data were 
expressed in logarithmic scale, and heat maps were generated using the rank product algorithm41. The analyses 
were performed using R software. The dataset was uploaded to the Gene Expression Omnibus (GEO) database 
(GSE100107).
In situ hybridization by RNAscope. In situ hybridization for HOTAIR was performed using the RNAscope 
2.5 HD assay kit according to the manufacturer’s protocol (Advanced Cell Diagnostics, Hayward, CA, USA)42. In 
brief, formalin-fixed, paraffin-embedded 7-μm tissue sections were deparaffinized and pretreated with protease 
for hybridization with HOTAIR target mixture probes. After hybridization, a series of signal-amplification steps 
were hybridized to the target probes followed by color development with Fast Red. Positive staining was identified 
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as red punctate dots in the cell. Negative control probes (DapB) and positive control probes (PPIB) were also 
tested for each slide to check the quality of hybridization.
Immunohistochemistry. For IGFBP2 immunostaining, paraffin-embedded, formalin-fixed 3-μm tissue 
sections from human RCC patients were deparaffinized in xylene and rehydrated by washing with a series of 
ethanol dilutions and distilled water. Heat-induced epitope retrieval was performed by microwaving the sections 
in a pH-9.0 target-retrieval solution (Dako, Produktionsvej, Denmark). Endogenous peroxidases were blocked 
with 0.3% H2O2. The sections were incubated with anti-human IGFBP2 for 12 h (1:1,000) at 37 °C, then with 
mouse LINKER (Dako) for 15 min, followed by incubation with the secondary antibody and development with 
3,3′-diaminobenzidine (DAB) chromogen (EnVision Detection Systems Peroxidase/DAB, Rabbit/Mouse, Dako).
Statistical analysis. All data from both in vitro and in vivo analyses were analyzed for statistical significance 
by Mann-Whitney U test, and P < 0.05 was considered significant. All statistical analyses were performed using 
JMP 11 (SAS Institute, Cary, NC, USA) and GraphPad Prism software (Version 6.05; GraphPad Software Inc., La 
Jolla, CA, USA).
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